Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
CD28 superagonists (CD28SAs) are potent T‐cell‐activating monoclonal antibodies (mAbs). In contrast to their benign behavior and marked therapeutic efficacy as activators of regulatory T (Treg) cells in preclinical rodent models, a phase I trial of the human CD28SA TGN1412 (now called TAB08) in 2006 resulted in a life‐threatening cytokine release syndrome (CRS). We studied TAB08‐mediated Treg‐cell activation in a recently developed in vitro system of human PBMCs, which also reproduces the CRS experienced by the healthy volunteers. We show that just as in rodents, CD28SAs are potent activators and expanders of Treg cells from healthy donors and rheumatoid arthritis patients, even under effective blockade of pro‐inflammatory cytokine release by a corticosteroid. Moreover, CD28SA titration identifies a dose range where pro‐inflammatory cytokine secretion from conventional T cells is absent while appreciable Treg‐cell activation is maintained. Finally, we report that low‐dose application of TAB08 to healthy volunteers results in dose‐dependent systemic release of the Treg‐cell signature cytokine IL‐10 in the absence of the pro‐inflammatory factors associated with the CRS of the 2006 TGN1412 study. These results demonstrate the potential of appropriately dosed CD28SA and corticosteroid comedication to mobilize human Treg cells for the treatment of autoimmune and inflammatory conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“lowering the concentration of TAB08 identified a dose range where proinflammatory cytokine release was absent but Treg activation was still observed [53].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“inclusion of methyl-prednisolone, a corticosteroid routinely used to fight episodes of CRS in the clinic, effectively suppressed an in vitro cytokine storm triggered by high CD28SA concentrations while leaving Treg activation and expansion partially intact [53].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“scrutiny of the healthy volunteers 0 plasma revealed no detectable cytokines but one: the Treg signature cytokine IL-10, an important anti-inflammatory mediator which was transiently found at significant levels in the two groups receiving the highest doses of TAB08 (Fig. 3).”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“These observations were not only made with PBMC samples from healthy donors but also from cohorts of RA [53], MS, SLE, and psoriasis patients (unpublished).”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“The recently published [53] results were a relief: not only was the drug well tolerated at these doses”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
Ehrenstein, M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D. A., & Mauri, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040165 · Cited by 1,252
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation
Tang, Q., & Bluestone, J. A. (2008) · Nature Immunology · doi:10.1038/ni1572 · Cited by 1,031
Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function
Furtado, G. C., de Lafaille, M. A. C., Kutchukhidze, N., & Lafaille, J. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020190 · Cited by 625
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T., & Thompson, C. B. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4472 · Cited by 566
Thornton, A. M., Donovan, E. E., Piccirillo, C. A., & Shevach, E. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6519 · Cited by 560
Nie, H., Zheng, Y., Li, R., Guo, T. B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3085 · Cited by 515
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Cited by
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Weirather, J., Hofmann, U. D. W., Beyersdorf, N., Ramos, G. C., Vogel, B., Frey, A., Ertl, G., Kerkau, T., & Frantz, S. (2014) · Circulation Research · doi:10.1161/circresaha.115.303895 · Cited by 699
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Metadata
- Authors
- Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T.
- Affiliations
- University of Würzburg (DE)
- TheraMAB LLC Würzburg Germany
- TheraMAB LLC Moscow Russian Federation
- Universitätsklinikum Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2014-02
- Volume
- 44
- Issue
- 4
- Pages
- 1225-1236
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1570409954
- Cited by
- 97
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 16 · 2015: 17 · 2014: 11
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Immunology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB-TR52)
- TheraMab LLC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- regulatory T cells, TGN1412, cytokine release syndrome, low-dose immunotherapy, IL-10, rheumatoid arthritis, autoimmune disease therapy, dose titration, human peripheral blood mononuclear cells
- MeSH terms
- Adrenal Cortex Hormones, Arthritis, Rheumatoid, Cells, Cultured, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Leukocytes, Mononuclear, Lymphocyte Activation, Cytokines, Interleukin-10, CD28 Antigens, Inflammation Mediators, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08. https://app.cochat.ai/papers/10.1002/eji.201343967
- The paper
- Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014). Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08. European Journal of Immunology. https://doi.org/10.1002/eji.201343967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.